Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants

Keyphrases

• Antidepressant Efficacy 33%
• Antidepressant Treatment Response 33%
• Antidepressants 100%
• BeadChip 33%
• Biomarkers of Response 33%
• Blood DNA 33%
• Blood RNA 33%
• CHN2 100%
• Clinical Significance 33%
• CpG Sites 33%
• Depression Rating Scales 33%
• Differential Methylation 33%
• Differentially Expressed Genes 33%
• Differentially Methylated Positions 66%
• DNA Gene 33%
• DNA Methylation Analysis 100%
• Epigenetic Marks 33%
• Escitalopram Treatment 33%
• Expression Change 33%
• Functional Components 33%
• Functional Predictor 100%
• Gene Expression Analysis 33%
• Genome-wide Approaches 33%
• Genome-wide DNA Methylation 33%
• Genome-wide Expression 100%
• Healthy Participants 33%
• Hypothesis-driven 33%
• Infinium MethylationEPIC BeadChip 33%
• Janus Kinase 2 (JAK2) 66%
• Major Depressive Disorder 66%
• Montgomery 33%
• MRNA Expression 33%
• Non-responders 100%
• Peripheral Blood 33%
• Response Predictors 100%
• Sequence Method 33%
• Targeted Sequencing 33%
• Treatment Response 33%

Biochemistry, Genetics and Molecular Biology

• Alpha 1-Antitrypsin 50%
• CpG Site 50%
• DNA Methylation 50%
• Epigenetics 50%
• Escitalopram 50%
• Expression Analysis 100%
• Gene Expression Profiling 50%
• Janus Kinase 100%
• Messenger RNA 50%
• Methylation 100%
• RNA 50%

Neuroscience

• Alpha 1-Antitrypsin 20%
• Antidepressant 100%
• CpG Site 20%
• DNA Methylation 20%
• Escitalopram 20%
• Expression Analysis 100%
• Gene Expression 20%
• Janus Kinase 40%
• Major Depressive Disorder 40%
• Methylation 100%